IQAIR TO RELEASE 2024 WORLD AIR QUALITY REPORT, REVEALING CHANGES TO GLOBAL AIR QUALITY AND ITS HEALTH IMPACTS
WHAT: IQAir's 7th annual World Air Quality Report presents a detailed global air pollution analysis, tracking exposure to harmful PM2.5 air pollution across 138 countries, territories, and regions, spanning 8,956 locations. The report is based on data from more than 40,000 air quality monitoring stations worldwide, offering the most comprehensive snapshot of global air pollution to date.
WHEN: The 2024 World Air Quality Report will be publicly released on Tuesday, March 11, at 12:01 a.m. Eastern Time (04:00 UTC). Credentialed journalists can request embargoed access to the report and interviews ahead of the release.
WHY: IQAir's latest findings reveal millions of people continue to breathe polluted air, endangering their health and well-being. The 2024 World Air Quality Report will analyze:
The most polluted countries and cities of 2024
The percentage of countries meeting the World Health Organization's (WHO) annual PM2.5 guideline
The impact of 2024 weather trends on global air pollution
How data was collected and analyzed to uncover key trends
Potential solutions individuals, groups, and governments can take to tackle air pollution problems
WHERE: The full 2024 World Air Quality Report will be available at www.iqair.com/us after the embargo lifts. Embargoed findings and interviews can be requested before the official release.
WHO: The following are available for media interviews on report findings and health impacts of air pollution:
Frank Hammes, Global CEO, IQAir
Glory Dolphin Hammes, CEO North America, IQAir
Dr. Christi Chester Schroeder, Air Quality Science Manager, IQAir
HOW: To request embargoed report findings or an embargoed interview, contact Armen Araradian at pr.na@iqair.com.
ABOUT IQAir:
IQAir is a Swiss technology company that empowers individuals, organizations, and governments to improve air quality through information, collaboration, and intervention.
For press inquiries, interviews, and media coverage please contact:
Armen Araradianpr.na@iqair.com+1 (562) 315-6010
View original content to download multimedia:https://www.prnewswire.com/news-releases/iqair-to-release-2024-world-air-quality-report-revealing-changes-to-global-air-quality-and-its-health-impacts-302376013.html
SOURCE IQAir
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Rare rattlesnake at University of Michigan's Matthaei Botanical Gardens captured on video
It's a unique sight — a threatened Eastern massasauga rattlesnake surrounded by her brood of offspring and out visible for all to see. The rattlesnake named Gertrude, or Gertie, took shelter in the opening of a drainpipe earlier this summer and gave birth around late July or early August at the University of Michigan's Matthaei Botanical Gardens, the Detroit Free Press previously reported. Now, there's additional video to share thanks to the team at the botanical gardens and Nichols Arboretum. The video shows a slithering mass of babies and mom on a sunny day in the gardens in Ann Arbor Township. Roughly 12 baby snakes were spotted, Steven Parrish, natural areas specialist for the gardens, Nichols Arboretum and two other properties, previously told the Free Press. Michigan is the last stronghold for the threatened rattlesnake, which is the state's only venomous snake, Parrish said, and the botanical gardens are committed to restoring and protecting their habitat. In his more than a decade of work at the site, Parrish said he's only ever seen two snakes together. That makes the swarm of family notable. More: Eastern massasauga rattlesnake gives birth at University of Michigan botanical gardens The gardens have signs to alert visitors and experts highlight that bites are fairly rare and that the snakes are mainly hoping people walk past them without the need to interact. For more on Gertie the rattlesnake, the birth of her babies and the story of the threatened species, check out the Free Press' original story on the discovery. This article originally appeared on Detroit Free Press: Rattlesnake at University of Michigan gardens captured on video Solve the daily Crossword
Yahoo
5 hours ago
- Yahoo
IBM and NASA Release Groundbreaking Open-Source AI Model on Hugging Face to Predict Solar Weather and Help Protect Critical Technology
The first heliophysics AI foundation model trained on high resolution solar observation data offers insights into the Sun's dynamic surface, helping plan for solar weather that can disrupt technology on Earth and in space Openly available on Hugging Face, the model was built to speed up scientific discovery and democratize AI for the global research and technology community Researchers also release the largest known curated heliophysics dataset to advance data driven space weather research YORKTOWN HEIGHTS, N.Y., Aug. 20, 2025 /PRNewswire/ -- IBM (NYSE: IBM) and NASA today unveiled the most advanced open-source foundation model designed to understand high resolution solar observation data and predict how solar activity affects Earth and space-based technology. Surya, named for the Sanskrit word for the Sun, represents a significant advancement in applying AI to solar image interpretation and space weather forecasting research, providing a novel tool to help protect everything from GPS navigation to power grids to telecommunications from the Sun's ever-changing nature. The Sun may be 93 million miles away, but its impact on modern life is immediate and growing. Solar flares and coronal mass ejections can knock out satellites, disrupt airline navigation, trigger power blackouts, and pose serious radiation risks to astronauts. With humanity's increasing dependence on space-based technology and plans for deeper space exploration, accurate solar weather prediction has become critical. As humanity's technological dependence grows, so does our vulnerability to space weather. According to a systemic risk scenario created by Lloyd's, the global economy could be exposed to losses of $2.4 trillion over a five-year period, with the expected loss of $17 billion from the threat of a hypothetical solar storm. Recent solar events1 have already demonstrated the risk, disrupting GPS services, forcing flight diversions, and damaging satellites. The effects of solar storms can cause: Damage to satellites, spacecraft and/or astronauts that are stationed beyond Earth Loss of satellite hardware, damaging solar panels and circuits Impact to airline travel, due to navigational errors and potential risk of radiation for airline crew and passengers Lowered food production as agriculture can be impacted by disrupted GPS navigation The implications include both academic research and operational preparedness. The new model will provide tools to help experts plan for solar storms, which can disrupt the Earth's technological infrastructure. "Think of this as a weather forecast for space," said Juan Bernabe-Moreno, Director of IBM Research Europe, UK and Ireland. "Just as we work to prepare for hazardous weather events, we need to do the same for solar storms. Surya gives us unprecedented capability to anticipate what's coming and is not just a technological achievement, but a critical step toward protecting our technological civilization from the star that sustains us." Traditional solar weather prediction relies on partial satellite views of the Sun's surface, historically making accurate forecasting extremely difficult. Surya addresses this typical limitation by training on the largest curated high resolution heliophysics dataset. This dataset is designed to help researchers better study and evaluate critical space weather prediction tasks. Examples of these tasks, which Surya has been tested on, include predicting solar flares, the speed of solar winds, solar EUV spectra prediction and the emergence of active regions on the Sun. In early testing, researchers report achieving a 16 percent improvement in solar flare classification accuracy, which researchers report as a very substantial improvement compared to previous methods. In addition to the binary solar flare classification task, Surya is built to visually predict solar flares for the first time, providing a high resolution image of where the flare is predicted to occur up to two hours out. The technical challenges were immense. Surya was trained on nine years of high-resolution solar observation data from NASA's Solar Dynamics Observatory. These solar images are 10 times larger than typical AI training data, requiring a custom multi-architecture solution to handle the massive scale while maintaining efficiency. The result is a model with unprecedented spatial resolution that can resolve solar features at scales and contexts not previously captured in large-scale AI training workflows. "We are advancing data-driven science by embedding NASA's deep scientific expertise into cutting-edge AI models," said Kevin Murphy, chief science data officer at NASA Headquarters in Washington. "By developing a foundation model trained on NASA's heliophysics data, we're making it easier to analyze the complexities of the Sun's behavior with unprecedented speed and precision. This model empowers broader understanding of how solar activity impacts critical systems and technologies that we all rely on here on Earth." Surya is part of a broader effort at IBM to embrace generative and automated approaches that empower algorithms to be discovered, tested, and evolved at scale. Surya is one example of how IBM is positioning AI not just as a tool, but as a driver of scientific discovery. By releasing Surya on Hugging Face, IBM and NASA are democratizing access to advanced tools for understanding and forecasting solar weather and scientific exploration. Researchers worldwide can now build upon this foundation to develop specialized applications for their regions and industries. This model is part of a larger collaboration between IBM and NASA to use AI technology to explore our planet and solar system. It joins the Prithvi family of foundation models, which includes a geospatial model and a weather model. Last year, IBM and NASA released the Prithvi weather model on Hugging Face for scientists and the broader community to develop short- and long-term weather and climate projections. About IBMIBM is a leading provider of global hybrid cloud and AI, and consulting expertise. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Thousands of government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM's hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM's breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and consulting delivers open and flexible options to our clients. All of this is backed by IBM's long-standing commitment to trust, transparency, responsibility, inclusivity and service. Media ContactAshley PetersonIBM Research 1 Interplanetary Causes and Impacts of the 2024 May Superstorm on the Geosphere: An Overview – IOPscience. Interplanetary Causes and Impacts of the 2024 May Superstorm on the Geosphere: An Overview, Hajra, Rajkumar, Tsurutani, Bruce Tsatnam, Lakhina, Gurbax Singh, Lu, Quanming, Du, Aimin. View original content to download multimedia: SOURCE IBM
Yahoo
6 hours ago
- Yahoo
Human Microbiome Market worth $7.09 billion by 2031 with 31.0% CAGR
DELRAY BEACH, Fla., Aug. 20, 2025 /PRNewswire/ -- The global Human Microbiome Market, valued at US$0.91 billion in 2024, stood at US$1.40 billion in 2025 and is projected to advance at a resilient CAGR of 31.0% from 2025 to 2031, culminating in a forecasted valuation of US$7.09 billion by the end of the period. The primary drivers behind the expansion of this industry are the technological advancement in microbiome sequencing, the collaborative efforts between the microbiome industry, organizations, and academia for microbiome research, and the increase in the number of startups and SMEs exploring the microbiome niche, and further opportunities such as the increase in demand for personalized medicine and the emergence of synbiotics may help drive the human microbiome market. Download PDF Brochure: Browse in-depth TOC on "Human Microbiome Market" 416 - Tables64 - Figures371 - Pages By type, bacterial consortia transplantation (BCT)/ fecal microbiota transplantation (FMT), live bacteria products, and others segment the human microbiome market. Live bacteria products accounted for the largest share of the human microbiome market in 2024. This category includes probiotics and synbiotics, which are widely used in consumer health supplements and emerging therapeutic applications. The dominance of live bacteria products is driven by strong consumer demand for digestive and immune health solutions, along with increasing clinical validation of specific bacterial strains. These products are often easier to formulate, regulate, and distribute compared to more complex microbiome therapies, allowing for faster commercialization. Additionally, ongoing advancements in encapsulation and delivery technologies have improved bacterial stability and survivability through the gastrointestinal tract, enhancing their effectiveness. The growing focus on personalized nutrition and preventive health has further expanded the adoption of live bacteria products across various age groups and health segments. Fecal microbiota transplantation/biological combination therapies (FMT/BCT) accounted for the second-largest share, supported by approved drugs such as VOWST and Rebyota for recurrent Clostridioides difficile infection. By end users, the human microbiome market is segmented by end users, hospitals & clinics, long-term care facilities, and other end users. Hospitals and clinics accounted for the largest share of the human microbiome market in 2024. This is largely due to their critical role in administering, monitoring, and regulating microbiome-based therapeutics, particularly those targeting infectious and gastrointestinal conditions. Approved products such as VOWST and Rebyota, used to prevent recurrent Clostridioides difficile infection, are typically prescribed and delivered in clinical settings under medical supervision. These facilities provide the necessary infrastructure for managing live microbial therapies, which may require cold-chain storage, specialized handling, and follow-up care. Hospitals and clinics are also key sites for clinical research, including patient enrollment for microbiome-based drug trials and real-world evidence studies. Their involvement enables close monitoring of patient outcomes, adverse events, and long-term therapeutic effects, all of which are essential for the advancement of microbiome science and regulatory approval processes. Moreover, the rising prevalence of chronic conditions linked to microbiome imbalance, such as inflammatory bowel disease and metabolic disorders, has led to increased hospital-based consultations and treatment protocols involving microbiome interventions. The presence of trained healthcare professionals, diagnostic tools, and institutional trust further supports the strong uptake of microbiome products within hospital and clinical environments. By geography, in 2024, North America accounted for the largest share of the human microbiome market. This leading position is supported by a well-established biotechnology ecosystem, strong research and development infrastructure, and the presence of major market players such as Seres Therapeutics, Seed Health, and IFF. The region has seen significant regulatory progress, with the US FDA approving the first microbiome-based drugs, including Rebyota and VOWST, for the prevention of recurrent Clostridioides difficile infection. These approvals have encouraged further investment in microbiome therapeutics and supplements. North America also has high adoption rates for probiotics, prebiotics, and synbiotics, driven by increasing consumer awareness of gut health and preventive wellness. The region supports a growing number of clinical trials and academic collaborations focused on the role of microbiomes in conditions such as gastrointestinal diseases, metabolic disorders, and cancer. Additionally, favorable healthcare spending, innovation funding, and regulatory clarity continue attracting startups and established firms. These combined factors reinforce the dominant position of North America in the global human microbiome market. Request Sample Pages : Some of the leading players in the market include Seres Therapeutics (US), Ferring B.V. (Switzerland), BiomeBank (Australia), Seed Health, Inc. (US), International Flavors & Fragrances Inc. (US), Pendulum (US), Biohm Technologies (US), Actial Farmaceutica Srl (Italy), OptiBiotix Health Plc (UK), resbiotic (US), Infinant Health Inc. (US), BioGaia (Sweden), and ExeGi Pharma (US), among others. Seres Therapeutics (US): Seres Therapeutics is one of the emerging players in the human microbiome market. The company's microbiome therapeutics platform significantly reduces the time typically required to advance therapeutics to the clinic and, ultimately, to the market. The company focuses on R&D to launch advanced products in the market. Its R&D expenses were USD 64.6 million for the year ending December 31, 2024. It specializes in creating oral live biotherapeutic products with defined bacterial consortia intended to modulate the human microbiome. Its lead product, VOWST (formerly SER-109), received FDA approval in April 2023 to prevent recurrent Clostridioides difficile infection. VOWST is the first FDA-approved orally administered microbiome therapeutic. In 2023, Seres Therapeutics implemented organizational changes, including workforce reductions and a narrowed R&D focus. In June 2024, the company entered into an agreement with Nestlé Health Science to transfer full commercialization rights for VOWST. The company continues to pursue clinical development of its remaining programs and maintains collaborations with academic and industry partners. FERRING B.V. (SWITZERLAND) Ferring Pharmaceuticals is a biopharmaceutical company involved in the development of microbiome-based therapeutics. The company operates in multiple therapeutic areas, including reproductive medicine, maternal health, gastroenterology, and urology. Ferring engages in internal research and external partnerships in the microbiome space. It acquired Rebiotix, a company developing live biotherapeutic products targeting the human microbiome. The company developed Rebyota, a fecal microbiota-based therapeutic indicated for preventing recurrent Clostridioides difficile infection. The product received FDA approval in November 2022 and is administered via enema. It has also collaborated with organizations such as Karolinska Institutet, Intralytix, MyBiotics, and PharmaBiome to explore live microbial consortia, bacteriophage-based therapies, and microbiome diagnostics. The company maintains manufacturing and R&D operations in various regions and continues to advance its microbiome programs across therapeutic categories through preclinical and clinical development stages. International Flavors & Fragrances Inc. (US) International Flavors & Fragrances (IFF) operates in the fields of flavor, fragrance, nutrition, and biosciences, with a growing focus on microbiome-based ingredients. The company has developed capabilities in precision fermentation and microbial strain engineering, enabling the industrial-scale production of next-generation probiotics, including strict anaerobes like Akkermansia. These technologies support ingredient development for applications in human and pet health, food, and supplements. IFF's HOWARU brand includes clinically studied probiotic strains such as HN001, HN019, NCFM, Bi-07, and Bl-04. These strains are formulated for specific health outcomes, including immune support, digestive health, stress response, early life development, and healthy aging. HN001 has regulatory recognition in markets like Brazil for reducing eczema risk in infants and pregnant women. IFF offers products such as HOWARU Protect and HOWARU Restore, each targeting different stages of life or health needs. The HOWARU brand includes clinically studied probiotic strains such as HN001, HN019, NCFM, Bi-07, and Bl-04. These strains are formulated for specific health outcomes, including immune support, digestive health, stress response, early life development, and healthy aging. HN001 has regulatory recognition in markets such as Brazil for reducing eczema risk in infants and pregnant women. IFF offers products like HOWARU Protect and HOWARU Restore, each targeting different stages of life or health needs. The microbiome innovation of IFF is supported by ongoing collaborations and a broader portfolio in synthetic biology, enabling the development of functional ingredients across consumer and health product categories. For more information, Inquire Now! Related Reports: Clinical Microbiology Market High Throughput Screening Market Microbiome Sequencing Services Market Rapid Microbiology Testing Market Laboratory Proficiency Testing Market Get access to the latest updates on Human Microbiome Companies and Human Microbiome Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets 登入存取你的投資組合
